This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
by Zacks Equity Research
Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.
RARENegative Net Change ALDXPositive Net Change ACIUNegative Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
by Ahan Chakraborty
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
RXRXNegative Net Change SDGRNegative Net Change RLAYNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
QURE Submits Application for Gene Therapy for Huntington's Disease
by Zacks Equity Research
QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
QURENegative Net Change RGENPositive Net Change ANIKNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
by Ekta Bagri
Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
CYTKPositive Net Change BMYNegative Net Change EWTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
by Zacks Equity Research
Novartis' remibrutinib delivers positive phase III RMS results, reducing relapse rates versus Aubagio and supporting plans for global regulatory approvals.
NVSNegative Net Change RGENPositive Net Change ANIKNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK to Advance mRNA Influenza Vaccine Into Phase III Development
by Zacks Equity Research
GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.
GSKNegative Net Change MRNANegative Net Change RGENPositive Net Change ANIKNegative Net Change
biotechs
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
by Zacks Equity Research
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
OCGNNegative Net Change RGENPositive Net Change ANIKNegative Net Change PGENNegative Net Change
biotechs
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
by Ahan Chakraborty
Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.
LLYNegative Net Change MRKNegative Net Change GILDNegative Net Change ABBVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
by Ekta Bagri
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
GILDNegative Net Change GSKNegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal
by Zacks Equity Research
LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.
LLYNegative Net Change SNYNegative Net Change BMYNegative Net Change
biotechs medical pharmaceuticals